Opening book details…
Can I read A Randomized, Controlled, Multicenter, Safety and Efficacy Study of FCR001 Cell-Based Therapy Relative to a Tacrolimus- and Mycophenolate-Based Regimen in De Novo Living-Donor Kidney Transplant Recipients, and Safety in FCR001 Donors (FREEDOM-1 study) on EtoBox?
A Randomized, Controlled, Multicenter, Safety and Efficacy Study of FCR001 Cell-Based Therapy Relative to a Tacrolimus- and Mycophenolate-Based Regimen in De Novo Living-Donor Kidney Transplant Recipients, and Safety in FCR001 Donors (FREEDOM-1 study) by Joseph R. Leventhal; Gordon Ingle; Kristi Schneider; Nancy R Krieger; Suzanne T Ildstad is a Medicine article available to read on EtoBox.
What is A Randomized, Controlled, Multicenter, Safety and Efficacy Study of FCR001 Cell-Based Therapy Relative to a Tacrolimus- and Mycophenolate-Based Regimen in De Novo Living-Donor Kidney Transplant Recipients, and Safety in FCR001 Donors (FREEDOM-1 study) about?
Transplant Cell Ther 29 2S (2021) S1-S468 follow-up, with all deaths directly due to relapse (Fig) . The incidence of GVHD post-DLI was 51%. ## Conclusion: We validate the high clinical efficacy of RIC HSCT in older patients with myeloid disease and show that within our cohort, age did not associate with higher treatment-related or overall mortality. The strategic use of DLIs is a potent immunomodulatory tool that can optimize graft-versus-tumor effects in high-risk patients.
Who reads A Randomized, Controlled, Multicenter, Safety and Efficacy Study of FCR001 Cell-Based Therapy Relative to a Tacrolimus- and Mycophenolate-Based Regimen in De Novo Living-Donor Kidney Transplant Recipients, and Safety in FCR001 Donors (FREEDOM-1 study)?
It is typically read by researchers, students, and practitioners in Medicine.
- Author
- Joseph R. Leventhal; Gordon Ingle; Kristi Schneider; Nancy R Krieger; Suzanne T Ildstad
- Publisher
- Elsevier BV
- Published
- 2023
- Language
- EN
- Field
- Medicine (Health Sciences)